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Abstract: 
 
Background:  Guidelines recommend that patient decision aids provide quantitative information 
about probabilities of potential outcomes, but the impact of this information is unknown.  
Behavioral economics suggests that patients confused by quantitative information could benefit 
from a “nudge” towards one option.  We conducted a pilot randomized trial to estimate the effect 
sizes of presenting quantitative information and a nudge. 
 
Methods:  213 primary care patients eligible for colorectal cancer screening viewed basic 
screening information and were randomized to view (a) quantitative information (quantitative 
module), (b) a nudge towards stool testing with the fecal immunochemical test (FIT) (nudge 
module), (c) neither a nor b, or (d) both a and b.  Outcome measures were perceived colorectal 
cancer risk, screening intent, preferred test, and decision conflict, measured before and after 
viewing the decision aid, and screening behavior at 6 months. 
 
Results:  Patients viewing the quantitative module were more likely to be screened than those 
who did not (p=0.012).  Patients viewing the nudge module had a greater increase in perceived 
colorectal cancer risk than those who did not (p=.041).  Those viewing the quantitative module 
had a smaller increase in perceived risk than those who did not (p=.046), and the effect was 
moderated by numeracy.  Among patients with high numeracy who did not view the nudge 
module, those who viewed the quantitative module had a greater increase in intent to undergo 
FIT (p=.028) than did those who did not.  
 
Limitations:  Limited sample size and single healthcare system. 
 
Conclusions:  Adding quantitative information to a decision aid increased uptake of colorectal 
cancer screening, while adding a nudge to undergo FIT did not increase uptake.  Further research 
on quantitative information in decision aids is warranted. 
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Introduction: 
 
Quantitative Information and Colorectal Cancer Screening: 
Decision aids aim to improve patient decision-making in preference-sensitive situations, 
i.e. where there is no single medically favored option.1-5  A critical question is how or what 
information decision aids should provide.  Many experts recommend that decision aids disclose 
probabilities of possible outcomes to support fully informed decisions.4,6-10  For decision aids 
regarding screening tests, guidelines such as the International Patient Decision Aids Standards 
(IPDAS) recommend that decision aids disclose absolute risk, risk reduction and the chance of 
negative outcomes.4,7 
It is unclear, however, whether quantitative information improves patient decisions.  
Describing risk with numbers or figures rather than verbally reduces patient concern and may 
increase willingness to accept treatment.11-14  But it is not clear whether these differences reflect 
improved decision-making.  Many individuals have difficulty interpreting and applying 
quantitative information: more than half of US adults do not understand simple mathematical 
concepts of percentage and frequency.15,16  Even when quantitative information is understood, 
heuristics and biases interfere with rational processing.17-19  According to some theories, when 
people learn numbers, they also store a separate “gist impression” that involves emotional factors 
and significantly affects behavior.18,20 
Previous studies have not directly measured the impact of including quantitative 
information in decision aids.  A recent Cochrane review of randomized, controlled trials of 
DAs21 identified 25 studies involving decision aids that presented probabilities. Patients who 
viewed decision aids with probabilities were more likely to correctly answer probability 
questions than controls, but presenting probabilities did not affect other outcomes.  Further, only 
1 of the 25 studies compared decision aids that were identical except for inclusion of 
probabilities, and this single trial used scripts read to elderly participants.22  Some experts have 
questioned whether all patients should be given detailed quantitative information and have called 
for additional research.23-27 
Colorectal cancer screening provides an excellent context to investigate the impact of 
presenting quantitative information.  While national guidelines recommend that all individuals 
aged 50-75 years undergo colorectal cancer screening, the choice of a screening test is 
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preference-sensitive, since multiple tests are approved.28-30  The two most common tests are 
colonoscopy every 10 years and annual stool testing,31 and each has important advantages and 
disadvantages.  While colonoscopy provides the most complete examination of the colon, 
patients must undergo an uncomfortable prep and face risks including bleeding and colon 
perforation. Stool testing, such as the fecal immunochemical test (FIT), is non-invasive and 
performed at home.  FIT has lower sensitivity than colonoscopy, must be repeated annually, and 
positive tests must be followed up with colonoscopy;28-30 however, when performed annually 
FIT may provide long-term risk reduction that rivals colonoscopy.32,33  Of the 7 colorectal cancer 
screening decision aids that have been tested in randomized controlled trials, 4 provided some 
quantitative information about the baseline risk of colorectal cancer, risk reduction provided by 
the two tests, or frequency of negative outcomes,22,34-36 while 3 did not.37-39 
 
Social norms 
Providing quantitative information about colorectal cancer screening tests might make 
patients unsure which to choose, and thus could delay screening.  Such a decline would be 
particularly unfortunate if it stemmed from confusion or misunderstanding.  The field of 
behavioral economics has designed and tested interventions, often called “nudges,”40,41 that 
utilize nonrational, nonconscious features of human thought to improve decisions.  For example, 
people are less likely to litter or cheat on their taxes if they believe that relatively few people do 
so (“social norms”).42-44  Some have suggested that nudges be used more frequently in 
medicine.40,45-47 
A social norms “nudge” towards one of the available colorectal cancer screening tests 
could help patients who are unsure which test to choose, perhaps due to being confused by 
quantitative data. FIT is a natural candidate for such nudging, since it is noninvasive and easy to 
perform.  Studies have found that offering FIT results in higher screening uptake than 
recommending colonoscopy.48,49   
In this paper, we report a pilot randomized controlled trial to test the impact of providing 
patients with quantitative information regarding colorectal cancer screening and of presenting a 
social norms nudge to FIT in a decision aid.  We used a 2x2 full-factorial between-subjects 
design with 6-month follow-up (Figure 1).  All patients viewed basic information regarding 
colorectal cancer screening tests and then were randomized to view (1) no further information 
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(Basic-Info-Only group), (2) quantitative information regarding colorectal cancer risk and 
screening tests (Quantitative group), (3) a nudge to undergo FIT (Nudge group), or (4) both 
quantitative information and the nudge (Quantitative+Nudge group).  We aimed to answer two 
research questions:   
1) In a decision aid regarding colorectal cancer screening, does the addition of (a) 
quantitative information, (b) a nudge to FIT, or (c) both, impact perceived colorectal 
cancer risk, intent to be screened, decision conflict, test preference, or uptake of 
screening at six months, compared to viewing basic information only? 
2) Does numeracy moderate any effects? 
Since this was the first study to measure the impact of providing quantitative information and a 
nudge to FIT, compared to basic information alone, our primary goal was to estimate effect sizes 
for consideration in designing a larger, fully-powered trial. 
 
Methods:  
 
Study Setting 
The study was conducted from August 2011 through February 2013 at five primary care 
sites in the Indiana University Health system serving a racially and ethnically diverse population 
of central Indiana.  The study was approved by the Indiana University Institutional Review 
Board. 
 
Inclusion/ Exclusion Criteria: 
Participants were screening-eligible male and female adults, 50 to 75 years old who were 
scheduled to be seen at participating primary care clinics.  Participants were eligible if they had 
not had colonoscopy in the last 10 years, sigmoidoscopy in the last 5 years, or stool blood test in 
the past year.  We excluded patients who: (1) had a diagnosis or family history conferring 
elevated risk for colorectal cancer, (2) were undergoing workup for symptoms consistent with 
colorectal cancer, (3) did not read English, or (4) were instructed by health care provider to avoid 
colorectal cancer screening. 
 
Recruitment process 
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Twenty-five primary care physicians at five participating practices were asked for 
consent to approach their eligible patients, and 24 (96%) agreed.  Patients who appeared to be 
eligible according to the electronic medical record were sent an introductory letter and contacted 
by phone to assess eligibility.  Eligible patients who agreed to participate met a study team 
member for approximately one hour in the clinic, often coinciding with a provider appointment. 
 
Study Procedure 
After providing written informed consent, participants completed a self-administered 
paper baseline survey (T0) in the presence of a research assistant who was available to answer 
questions. Participants were then randomly assigned to one of four experimental groups.  
The biostatistics team generated the randomization scheme with stratification based on 
practice site, gender, and age (50 to < 65 years old and 65-75 years old).  Group assignments 
were sealed in sequentially numbered opaque envelopes.  The research assistant determined the 
participant’s group assignment by opening the next sequentially numbered envelope from the 
appropriate strata and then displayed the appropriate decision aid on a laptop computer.  
 Immediately after viewing the decision aid, participants completed a self-administered 
paper post-intervention survey (T1).  Six months later, participants were contacted by phone to 
assess screening uptake (T2) and the electronic medical record was reviewed for confirmation of 
screening for patients who had signed a medical record release form (Figure 2). 
 
Decision Aids: 
Each decision aid consisted of PowerPoint slides with text, figures, and an audio track, 
viewed on a laptop controlled by the patient.  We created three modules and then combined these 
to create a decision aid for each group, as follows: 
• Basic information group:  Basic information module only; 
• Quantitative group:  Basic information module, followed by Quantitative module; 
• Nudge group:  Basic information module, followed by Nudge module 
• Quantitative+Nudge group:  Basic information module, followed by Quantitative module, 
followed by Nudge module. 
Each decision aid had identical introductory and concluding slides. 
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We designed initial versions of the modules based on the extensive literature regarding 
evidence-based communication,50-52 risk communication,9,10,18,20,53-56 behavioral 
economics,40,45,46,57,58 lifetime colorectal cancer incidence and mortality for average risk 
individuals,32 and patient preferences and interest in information about colorectal cancer 
screening.59-70  We reviewed a variety of models for risk reduction provided by colonoscopy and 
FIT,32,71-73 eventually choosing to use estimates provided by the SimCRC model.71,74,75   
Draft forms of the modules were reviewed by 3 experts in colorectal cancer screening and 
patient communication to evaluate face validity, message appropriateness, and clarity.  In 
addition, cognitive interviews were conducted with nine patients who were eligible for the study 
(but not enrolled) who viewed all modules to obtain feedback on their ability to comprehend the 
messages, graphs, and visuals.  Final edits were made to the modules based on expert and patient 
feedback.  See Appendix for sample slides from each module. 
The Basic Information module showed a six-minute video produced by the American 
Cancer Society that provides information about colorectal cancer and screening tests,76 followed 
by four PowerPoint slides summarizing advantages and disadvantages of colonoscopy and FIT.  
This module presented no quantitative information on risk or risk reduction. 
The Quantitative module included six slides with numbers and icon charts presenting the 
following values for average risk individuals: 
(1) lifetime colorectal cancer incidence (6%, or 60 per 1000) and colorectal cancer mortality 
(3%, or 30 per 1000), assuming no screening,  
(2) lifetime colorectal cancer mortality given regular screening with colonoscopy (0.46%, or 
4.6 per 1000) or with FIT (0.6%, or 6 per 1000), according to the SimCRC model,32 
(3) frequency of an individual FIT turning positive (50 per 1000) and of serious 
complications from colonoscopy (1-2 per 1000). 
The quantitative module concluded with a bar chart displaying average lifetime colorectal cancer 
mortality with no screening, with colonoscopy, and with annual FIT.   
The Nudge module included three slides that showed graphics and simple text, with an 
audio track delivering the following messages:   
(1) “Given the advantages and disadvantages of both tests, many people have a hard time 
deciding which test to choose.” 
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(2) “Many people who do not want a colonoscopy, or are unsure about which test to choose, 
get a stool test, and it’s a perfectly reasonable option.” 
(3) “The stool test protects you almost as much as colonoscopy.  Either test protects you 
much more than getting no screening at all.” 
(4) “And even if you choose to get the stool test now, you can always get a colonoscopy 
later.” 
(5) “In summary, if you don’t want to have a colonoscopy right now, or don’t know which 
test to choose, the stool test could be the right one for you.” 
These messages were chosen since they could be expected to encourage selection of the stool 
test, either rationally or based on non-rational mechanisms, often studied in the social influence 
literature42-44 or behavioral economics.40-41 Saying that “many people” choose the stool test, in 
message (2), suggests that a social norm favors this test, as does calling it “perfectly reasonable.” 
Message (3) encourages patients to see the two tests as similarly efficacious.  Message (4) aims 
to make the stool test attractive for those who wish to procrastinate regarding a final decision.   
 
Measures 
• Perceived risk of colorectal cancer was assessed at baseline (T0) and immediately post-
intervention (T1) using a single item:  “How likely is it that you will get colon cancer 
sometime during your life?” with a seven-point response option where 1 = very unlikely and 
7 = very likely. 
• Intent to be screened for colorectal cancer was measured at T0 and T1 with three separate 
items:  “Do you plan to get a [colon test / colonoscopy / stool test] within the next 6 
months?” each with response options of:  Definitely, Probably, May or may not, Probably 
not, and Definitely not.77  
• Test choice if screened was measured at T0 and T1 using a single item:  “If you have a colon 
test, which one would you choose?” Response options were:  Stool test, Colonoscopy, Other, 
Don’t Know. 
• Decision conflict was assessed at T0 and T1 using the Decision Conflict Scale, a sixteen-item 
instrument that assesses patients’ subjective feeling regarding the decision process over five 
areas.  Each item is a Likert-style question with five-point response option, where 1= 
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strongly agree and 5 = strongly disagree, summed to create a total Decision Conflict score.78  
The Cronbach alpha  was .94). 
• Numeracy was assessed at T1 with the Subjective Numeracy Scale, a validated instrument 
that involves 8 Likert-type questions regarding the individual’s preference for or dislike of 
numeric information and their perception of their ability to understand it. Each item has a six-
point response option, with items summed to create a total numeracy score.79,80 The 
Cronbach alpha was .85 
• Screening uptake was assessed by checking the patient’s EHR for documentation of stool test 
and colonoscopy completion within 6 months of enrollment. In addition, patients were asked 
to self-report during the six-month follow-up phone call (T2) whether they had a 
colonoscopy, stool test, or other colon test since enrollment.  For patients who did not give 
permission to check their EHR, self-report of screening behavior was accepted (5 in Basic 
Info Only, 5 in Quantitative, 8 in Nudge, and 4 in Quantitative+Nudge).  Patient reports of 
screening uptake were accepted even if a check of the EHR did not reveal report of a 
completed test, due to the possibility of obtaining these tests elsewhere (3 in Basic Info Only, 
3 in Quantitative, 1 in Nudge, and 2 in Quantitative+Nudge).   
For two patients (both in the Basic Info Only group), an apparent inconsistency 
regarding screening uptake was addressed by consensus of the research team.  A member of 
the research team reviewing the electronic health record for these patients found specific 
information suggesting they were mistaken to believe that they had a FIT test.  The principal 
investigator presented the information to the research team, resulting in consensus to change 
recorded screening behavior for one patient from FIT and colonoscopy to just colonoscopy, 
and, for the other patient, from FIT to no screening. 
 
Statistical Methods:   
All analyses were conducted using SAS Version 9.3 (Cary, NC). The significance level 
was set at 0.05. Due to the pilot nature of the study and limited number of outcomes, we did not 
perform multiple comparison adjustments.  Sample sizes were determined based on data from a 
preliminary uncontrolled study that showed an average increase in intent to undergo screening of 
approximately 0.5 standard deviations after viewing qualitative and quantitative information.  
We assumed the same increase for the Quantitative group and no change for the Basic Info Only 
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group after the intervention for intent to undergo screening in the current study. A sample size of 
64 per group was needed to detect this difference with 80% power using a two-sample t-test and 
level of significance 0.05.  As we intended to use analysis of covariance (ANCOVA) to analyze 
differences, we expected our power would be higher than 80% overall. 
All models described below included covariates for practice site, gender, and age (50 to < 
65 years old and 65-75 years old). For perceived risk, intent to screen, and decision conflict 
outcomes, the changes in scores from T0 to T1 were compared using ANCOVA models and 
treatment effects estimated from these models.  The T0 score for each of these outcome was 
treated as a covariate in these models.  First, to examine the effects of our two interventions, 
models were fit that included main effects for quantitative and nudge intervention and their 
interaction.  Next, to see if numeracy moderated the effects of either intervention, models were 
fit that included quantitative, nudge, numeracy (high vs low in relation to the median) and all 
higher-order interactions. For each model, interactions were removed if they were not 
significant.  This was done by removing the 3-way interaction first (if applicable), then two-way 
interactions one at a time by highest p-value.  To check for overall changes in scores over time 
(i.e., assuming no interactions or main effects), an intercept only model was used.   
“Test preference” was calculated from Screening Intent and Test choice if screened as 
follows. If the patient answered Definitely or Probably on the Screening Intent question, the 
answer on Test choice if screened was coded as the patient’s Test preference (Colonoscopy, FIT, 
or other).  Patients who answered May or May Not, Probably Not, or Definitely Not on 
Screening Intent were coded as having a Test preference of ‘Do not intend to be screened’.  
Patients who answered “Don’t Know” on Screening Intent or Test choice if screened were coded 
as having Test Preference of Don’t Know.  Test preference was examined before and after 
intervention and proportions of patients who changed their preference at all or from something 
other than FIT at T0 to FIT at T1 was calculated, then compared across groups using chi-square 
tests and logistic regression models. 
Finally, self-reported completion of screening tests at the 6 month phone interview was 
compared using logistic regression models.  As in the change models above, all interactions were 
initially included and removed if not significant.  In addition, we performed a sensitivity analysis 
for the two cases where screening status was determined by consensus, switching the yes/no 
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decision for uptake.  There was no impact on the results, so only the consensus results are 
reported. 
 
Results:   
 
Study Population: 
Overall, 227 patients were randomly assigned to Basic-Information-Only, Quantitative, 
Nudge, and Quantitative+Nudge groups (Figure 3).  Fourteen randomized patients were later 
excluded from analysis because they were found to be up-to-date with screening at enrollment, 
resulting in a final sample size of 52 for Basic Information Only, 56 for Quantitative, 53 for 
Nudge, and 52 for Quantitative+Nudge. Average age was approximately 56 years.  The majority 
of participants were female, and white.  There were no significant differences on demographic 
variables or outcomes at baseline (T0) between the groups (Table 1).   
Changes in Perceived Risk, Decision Conflict, and Intent to Screen from baseline (T0) to 
immediately post-intervention (T1) are depicted in Figure S1. Overall (i.e. ignoring intervention 
received), there were statistically significant increases (or decreases for Decision Conflict) for all 
outcomes (p<.001) from T0 to T1.  We examined whether the type of intervention received 
affected these changes (Research Question 1) and if numeracy moderated these effects (Research 
Question 2). 
 
Research Question 1:   
Perceived Risk, Intent to Screen, and Decision Conflict outcomes:  There were no 
interactions between the quantitative and nudge interventions for any of the outcomes (Table 2).  
Patients who viewed the quantitative intervention had a smaller increase in Perceived Colorectal 
Cancer Risk (p=0.046) than patients who did not.  Patients who viewed the nudge intervention 
had a significantly larger increase in Perceived Colorectal Cancer Risk (p=.041) than patients 
who did not. There were no significant effects of the quantitative or nudge intervention on 
Colorectal Cancer Screening Intent, FIT Intent, or Decision Conflict 
Test Preference: Descriptive statistics for screening test preferences before and after the 
interventions are shown in Table 3.  Post hoc tests using conditional logistic regression indicated 
that, overall, the percent that did not intend to screen was lower at T1 than at T0 (p < 0.001). 
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These decreases did not differ by intervention group (p = 0.39).  Overall, there were no group 
differences in the percent changing their preference from T0 to T1 (Table 4, p = .48).  From 37% 
to 50% of patients changed their test preference at T1.  When comparing the percent of patients 
who changed their preference from colonoscopy, don’t know, or none (i.e. not FIT) to FIT, 
changes ranged from 21% to 43%.  Again there were no group differences overall (Table 4, p-
value=0.148). 
Uptake:  Patients in the quantitative groups were more likely to complete a colorectal 
cancer screening test (p=0.012; Table 5). There were no other significant effects for the 
quantitative or nudge interventions.    
Post hoc, we used logistic regression to explore the potential effects of Perceived Risk on 
Uptake to explore whether it might mediate the effect of the intervention on uptake.  Perceived 
Risk at T1 was not associated with uptake. 
 
Research Question 2: 
Perceived Risk, Intent to Screen, and Decision Conflict outcomes: When including 
numeracy in the models, there were two significant interactions (Table 6).  The numeracy, 
quantitative intervention and nudge intervention three-way interaction was significant for FIT 
Intent (p=.025). Patients with high numeracy who did not view the nudge intervention had 
greater increases in FIT Intent when viewing the quantitative intervention compared with not 
viewing it (p = .028).  Among those with high numeracy who did view the nudge intervention 
and those with low numeracy (whether they viewed the nudge intervention or not), the 
quantitative intervention had no effect on FIT Intent.  
There was a significant two-way interaction between numeracy and the quantitative 
intervention for Perceived Risk (p=.003).  Among those with high numeracy, the two groups 
receiving quantitative information had smaller increases in Perceived Colorectal Cancer Risk 
(p<.001) than the two groups who did not; whereas the quantitative intervention had no effect on 
Perceived Colorectal Cancer Risk among those with low numeracy (p=.46). 
Finally, there were two significant main effects of numeracy for Colorectal Cancer 
Screening Intent (p=.008) and Decision Conflict (p=<.001).  Those with high numeracy had 
larger increases in Colorectal Cancer Screening Intent, and larger decreases in Decision Conflict 
than those with low numeracy.  
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Test preference:    In logistic regression, those with higher numeracy had greater odds of 
changing to FIT at T1 (p=.027, OR=2.16, 95% CI: 1.09, 4.27). However, there were no 
intervention group differences in change in test preference or change from not FIT to FIT by 
numeracy levels using logistic regression or chi-square tests (Table 4). 
Uptake:  As with the models not accounting for numeracy, only the quantitative effect for 
colorectal cancer uptake was significant (p = 0.015) (Table 5). 
 
Discussion:   
Our study is the first to use a randomized trial design to estimate the effects of adding 
quantitative information to a decision aid, providing a direct test of one aspect of current 
recommendations for the design of decision aids.  Our study is also the first to measure the 
impact of presenting a social norms nudge towards stool testing for colorectal cancer screening 
in a decision aid.  We had three notable findings.   
First, viewing quantitative information significantly increased uptake of screening at six 
months. This provides support for recommendations that decision aids disclose such information 
to patients. No impact on patient behavior has been found in randomized trials comparing more 
complex vs. simpler decision aid, out of 13 relevant trials included in a recent review.21  
The way we presented quantitative information may have influenced the observed impact 
on screening uptake.  First, the quantitative module presented information about colorectal 
cancer risk and risk reduction over a lifetime rather than a shorter period. The magnitude of risk 
and risk reduction is larger over longer timeframes, and larger numbers have been shown to have 
greater impact than smaller ones.81,82  Second, our quantitative module included a bar chart that 
can be seen as conveying relative risk information, since the Y-axis height is the baseline 
mortality rate. Research has shown that relative risk information has a larger impact than 
absolute risk on perception of benefit.83-85 
Our second notable finding is that viewing quantitative information significantly reduced 
perceived colorectal cancer risk, and this effect was moderated by numeracy. This is consistent 
with previous research. Studies have found that individuals overestimate their probability of 
getting or dying of cancer,86 and that being informed about the probability of dying of a cancer 
reduces estimates of risk.27,87  Previous research has also shown that people with higher 
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numeracy skills are more likely to be influenced by quantitative information than those with 
lower numeracy skills.88-90 
Third, viewing the social norms nudge significantly increased perceived colorectal cancer 
risk, although  the Nudge module did not include any information about the risk of developing 
colorectal cancer, and it had no significant effect on intent, test preference, or uptake. One 
possible explanation is that the intervention’s message that screening is widely employed may 
have led patients to conclude that colorectal cancer poses a serious risk. We anticipated that 
viewing the nudge would increase intent to undergo FIT and preference for this test, but we did 
not find this. In our study, the Basic Information module viewed by all patients explained that 
FIT is an approved option, so the additional encouragement to choose FIT provided by the nudge 
module may have had a relatively small effect compared to this more general information 
 
Limitations:   
Our study has several limitations.  First, there was limited power to detect effects of the 
interventions, overall and within sub-groups, due to sample size. It was assumed there would be 
no change from T0 to T1 in the Basic Info group and no consideration of numeracy in the a 
priori calculation. Effect sizes obtained from pilot studies should be interpreted with caution and 
not used as sole evidence to decide whether or not to conduct a larger trial.91  Second, we did not 
adjust for multiple testing.  For example, applying a Bonferroni correction to the five main 
outcomes (adjusted alpha level 0.01), only the two-way interaction of numeracy and quantitative 
on perceived risk and the main effects for numeracy on colorectal cancer screening intent and 
decision conflict in Research Question 2 remain significant. Third, we recruited patients from 
several clinics within a single healthcare system in a single Midwestern city. Fourth, we were 
unable to confirm screening uptake in the EHR for 15% of our participants, introducing a 
possible source of bias in our results. Finally, our quantitative module presented only some 
quantitative information using certain frames, and the nudge intervention used only some 
techniques, so other information or other ways of framing the information could have other 
effects.   
 
 Conclusion:  This paper reports the effects of adding two separate modules to a decision 
aid regarding colorectal cancer screening:  (1) quantitative information recommended by widely 
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accepted guidelines, and (2) a nudge towards stool testing.  Most notably, we found that 
quantitative information significantly increased uptake of screening at six months, while the 
nudge had no effect on uptake.  In addition, we found that quantitative information reduced 
perceived colorectal cancer risk overall, and this was moderated by numeracy.  These findings 
support further research on the impact of providing quantitative information to patients 
considering screening, especially given the possibility of increasing uptake of highly 
recommended and effective screening tests.  
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Table 1. Demographics and T0 Outcomes 
Category Value Basic Info Only 
(n=52) 
Quantitative 
(N=56) 
Default 
(n=53) 
Quantitative 
+ Default 
(N=52) 
p-value 
Age mean (SD) 56.8 (7.8) 56.5 (7.0) 56.8 (7.0) 56.2 (7.3) 0.97 
Age – below median numeracy  58.9 (8.7) 57.3 (8.2) 57.9 (7.8) 56.7 (7.2) 0.76 
Age – above median numeracy  53.5 (4.2) 55.9 (5.9) 55.6 (6.0) 55.6 (7.4) 0.55 
Gender Female 34 (65%) 36 (64%) 34 (64%) 36 (69%) 0.94 
 Male 18 (35%) 20 (36%) 19 (36%) 16 (31%)  
Race White 37 (71%) 42 (75%) 38 (72%) 39 (75%) 0.84 
 Black or African American 12 (23%) 11 (20%) 11 (21%) 12 (23%)  
 Other 2 (4%) 3 (5%) 2 (4%) 0 (0%)  
Education High school graduate/GED or less 15 (29%) 12 (21%) 9 (17%) 12 (23%) 0.77 
 Some college/technical school/trade school 13 (25%) 15 (27%) 18 (34%) 17 (33%)  
 College Graduate or higher 22 (42%) 29 (52%) 26 (49%) 23 (44%)  
Income Level <$20,000 4 (8%) 7 (13%) 7 (13%) 3 (6%) 0.70 
 $20,000 - $39,999 11 (21%) 8 (14%) 11 (21%) 8 (15%)  
 $40,000 - $59,999 11 (21%) 13 (23%) 12 (23%) 10 (19%)  
 >=$60,000 16 (31%) 24 (43%) 17 (32%) 26 (50%)  
Perceived CRC Risk mean (SD) 3.26 (1.61) 2.93 (1.32) 2.96 (1.60) 2.83 (1.13) 0.46 
CRC Screening Interest mean (SD) 3.25 (1.15) 3.59 (1.11) 3.58 (1.08) 3.54 (1.09) 0.34 
Colonoscopy Interest mean (SD) 3.13 (1.17) 3.30 (1.13) 3.36 (1.21) 3.35 (1.19) 0.75 
Fit Interest mean (SD) 2.65 (0.90) 2.95 (1.02) 2.94 (1.03) 2.85 (0.92) 0.37 
Decision Conflict mean (SD) 27.7 (10.7) 28.8 (12.8) 11.5 (8.26) 25.7 (11.7) 0.29 
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Table 2. Between Group Differences in change in Intent, Perceived Risk, and Decision Conflict: 
Variable Group N T0 (mean (SD)) 
T1 
(mean (SD)) 
Change (T1-T0) 
(mean (SD)) 
Final Model 
p-values 
Model Estimate ± 
Standard Error 
Perceived CRC Risk 
Basic Info Only 50 3.26 (1.61) 3.80 (1.51) 0.53 (1.28) Q: 0.055 
D: 0.050 
Q:  -0.32 ± 0.17 
D:  0.33 ± 0.17 Quant 55 2.93 (1.32) 3.07 (1.43) 0.15 (1.03) 
Default 53 2.96 (1.60) 3.71 (1.25) 0.80 (1.65) 
Quant+Default 52 2.83 (1.13) 3.57 (1.50) 0.75 (1.38) 
CRC Screening Intent 
Basic Info Only 52 3.25 (1.15) 3.77 (1.13) 0.52 (0.94) Q: 0.35 
D: 0.85 
Q:  0.11 ± 0.11 
D:  0.02 ± 0.11 Quant 56 3.59 (1.11) 4.16 (0.89) 0.57 (0.91) 
Default 53 3.58 (1.08) 4.08 (1.12) 0.49 (0.93) 
Quant+Default 52 3.54 (1.09) 4.08 (1.15) 0.54 (0.96) 
Colonoscopy Intent 
Basic Info Only 52 3.13 (1.17) 3.35 (1.22) 0.21 (0.70) Q: 0.41 
D: 0.058 
Q:  0.08 ± 0.10 
D:  -0.18 ± 0.10 Quant 56 3.30 (1.13) 3.48 (1.16) 0.18 (0.77) 
Default 53 3.36 (1.21) 3.26 (1.30) -0.09 (0.69) 
Quant+Default 52 3.35 (1.19) 3.43 (1.27) 0.08 (0.72) 
FIT Intent 
Basic Info Only 52 2.65 (0.90) 3.00 (1.28) 0.35 (1.15) Q: 0.25 
D: 0.54 
Q:  0.18 ± 0.16 
D:  0.10 ± 0.16 Quant 56 2.95 (1.02) 3.54 (1.28) 0.59 (1.32) 
Default 53 2.94 (1.03) 3.45 (1.32) 0.51 (0.99) 
Quant+Default 52 2.85 (0.92) 3.39 (1.23) 0.55 (1.29) 
Decision Conflict 
Basic Info Only 52 27.69 (10.70) 13.54 (9.04) -14.2 (12.01) Q: 0.63 
D: 0.30 
Q:  -1.48 ± 1.10 
D:  -1.13 ± 1.09 Quant 56 23.61 (11.41) 10.38 (8.91) -13.2 (10.34) 
Default 53 26.83 (12.79) 11.53 (8.26) -15.3 (12.87) 
Quant+Default 52 25.69 (11.65) 10.42 (7.48) -15.3 (11.95) 
Q=Quantitative, D=Default 
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Table 3: Test preference before and after intervention: 
Group 
Intend to be screened with Do not intend to be screened 
Colonoscopy Stool Testing (FIT) Don’t Know/Other*  
Basic Info Only (n=52)     
Before intervention (T0) 14 (27%) 5 (10%) 4 (8%) 29 (56%) 
After intervention (T1) 19 (37%) 12 (23%) 1 (2%) 20 (39%) 
Quantitative (n=56)     
Before intervention (T0) 19 (34%) 8 (14%) 2 (4%) 27 (48%) 
After intervention (T1) 23 (41%) 19 (34%) 4 (7%) 10 (18%) 
Default  (n=53)     
Before intervention (T0) 20 (38%) 4 (8%) 4 (8%) 25 (47%) 
After intervention (T1) 15 (28%) 24 (45%) 0 (0%) 14 (26%) 
Quantitative + Default (n=52)     
Before intervention (T0) 20 (39%) 4 (8%) 4 (8%) 24 (46%) 
After intervention (T1) 18 (35%) 17 (33%) 3* (6%) 14 (27%) 
 *One participant said other at this time point 
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Table 4: Changes in test preference from T0 to T1: 
Group 
Change in Preference Change from not FIT to FIT 
Overall Low Numeracy 
High 
Numeracy Overall 
Low 
Numeracy 
High 
Numeracy 
Basic Info Only  19/52 (37%) 10/32 (31%) 8/19 (42%) 10/47 (21%) 5/28 (18%) 5/18 (28%) 
Quantitative  28/56 (50%) 13/24 (54%) 15/32 (47%) 14/48 (29%) 6/20 (30%) 8/28 (29%) 
Default   25/53 (47%) 10/28 (36%) 15/25 (60%) 21/49 (43%) 7/26 (27%) 14/23 (61%) 
Quantitative + Default 21/52 (40%) 10/26 (39%) 11/26 (42%) 15/48 (31%) 7/25 (28%) 8/23 (35%) 
p-value for group comparison 0.48 0.35 0.56 0.148 0.76 0.070 
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Table 5:  CRC Uptake by Group and Numeracy Level 
 
Variable 
Basic Info 
Only 
n/N (%) 
Quantitative 
n/N (%) 
Default 
n/N (%) 
Default + 
Quantitative 
n/N (%) 
Final Model  
p-values 
MLE ± Standard 
Error Odds Ratio (95% CI) 
Overall 
CRC screening 
uptake 
14/52 (27%) 22/56 (39%) 15/53 (28%) 25/51 (49%) 
Q:  0.013 
D:  0.39 
Q:  0.73 ± 0.29 
D:  0.25 ± 0.29 
Q: 2.07 (1.17, 3.68) 
D: 1.29 (0.73, 2.28) 
FIT uptake 5/52 (10%) 7/56 (13%) 6/53 (11%) 10/51 (20%) 
Q:  0.24 
D:  0.34 
Q:  0.49 ± 0.42 
D:  0.39 ± 0.41 
Q: 1.64 (0.73, 3.69) 
D: 1.48 (0.66, 3.31) 
Colonoscopy 
uptake 
10/52 (19%) 16/56 (29%) 10/53 (19%) 15/51 (29%) 
Q:  0.093 
D:  0.97 
Q:  0.55 ± 0.33 
D:  0.0135 ± 0.32 
Q: 1.73 (0.91, 3.30) 
D: 1.01 (0.54, 1.91) 
Below Total 
Numeracy 
Median 
CRC screening 
uptake 
8/32 (25%) 10/24 (42%) 9/28 (32%) 10/25 (40%) 
Q:  0.017 
D:  0.41 
NM:  0.72 
Q:  0.70 ± 0.30 
D:  0.24 ± 0.29 
NM:  0.11 ± 0.29 
Q: 2.02 (1.13, 3.61) 
D: 1.27 (0.72, 2.25) 
NM: 1.11 (0.63, 7.97) 
FIT uptake 5/32 (16%) 3/24 (13%) 4/28 (14%) 4/25 (16%) 
Q:  0.22 
D:  0.35 
NM:  0.44 
Q:  0.52 ± 0.42 
N:  0.38 ± 0.41 
NM:  -0.32 ± 0.41 
Q: 1.68 (0.74, 3.81) 
D: 1.47 (0.66, 3.29) 
NM: 0.73 (0.32, 1.64) 
Colonoscopy 
uptake 
4/32 (13%) 7/24 (29%) 6/28 (21%) 6/25 (24%) 
Q:  0.126 
D:  1.000 
NM:  0.37 
Q:  0.51 ± 0.34 
D:  0.001 ± 0.32 
NM:  0.29 ± 0.33 
Q: 1.66 (0.87, 3.17) 
D: 1.00 (0.53, 1.89) 
NM: 1.34 (0.71, 2.54) 
Above Total 
Numeracy 
Median 
CRC screening 
uptake 
6/19 (32%) 12/32 (38%) 6/25 (24%) 15/26 (58%)    
FIT uptake 0/19 (0%) 4/32 (13%) 2/25 (8%) 6/26 (23%)    
Colonoscopy 
uptake 
6/19 (32%) 9/32 (28%) 4/25 (16%) 9/26 (35%)    
*n = number screened; N=Total N 
Q=Quantitative, D=Default, NM=Numeracy 
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Table 6. Between Group Differences in change in Intent, Perceived Risk, and Decision Conflict by numeracy (above/below the median): 
Variable Numeracy Category Group n 
T0 
(mean (SD)) 
T1 
(mean (SD)) 
Change (T1-T0) 
(mean (SD)) 
Final Model    
p-values 
Model Estimate ± Standard 
Error 
Perceived CRC Risk 
Below Median 
Basic Info Only 31 3.71 (1.66) 4.06 (1.41) 0.33 (1.03) Q:  0.069 
D:  0.075 
NM:  0.118 
NM*Q:  0.004 
Interaction: 
Q for Low NM:  
0.18 ± 0.23 (p=0.43) 
Q for High NM: 
 -0.79 ± 0.26 (p=0.001) 
Quant 23 2.96 (1.43) 3.43 (1.56) 0.48 (1.04) 
Default 28 2.96 (1.77) 3.42 (1.39) 0.58 (2.00) 
Quant+Default 26 2.81 (1.36) 4.00 (1.50) 1.20 (1.55) 
Above Median 
Basic Info Only 19 2.53 (1.26) 3.37 (1.64) 0.84 (1.57) 
Quant 32 2.91 (1.25) 2.81 (1.28) -0.09 (0.96) 
Default 25 2.96 (1.43) 4.00 (1.04) 1.04 (1.17) 
Quant+Default 26 2.85 (0.88) 3.15 (1.41) 0.31 (1.05) 
CRC Screening Intent 
Below Median 
Basic Info Only 32 3.00 (1.14) 3.53 (1.19) 0.53 (1.02) Q:  0.62 
D:  0.95 
NM:  0.002 
Q:  0.06 ± 0.11 
D:  0.01 ± 0.11 
NM:  0.36 ± 0.11 
Quant 24 3.75 (1.07) 4.13 (0.95) 0.38 (1.01) 
Default 28 3.50 (1.11) 3.71 (1.30) 0.21 (0.88) 
Quant+Default 26 3.35 (1.20) 3.85 (1.26) 0.50 (0.71) 
Above Median 
Basic Info Only 19 3.63 (1.12) 4.21 (0.92) 0.58 (0.77) 
Quant 32 3.47 (1.14) 4.19 (0.86) 0.72 (0.81) 
Default 25 3.68 (1.07) 4.48 (0.71) 0.80 (0.91) 
Quant+Default 26 3.73 (0.96) 4.31 (1.01) 0.58 (1.17) 
Colonoscopy Intent 
Below Median 
Basic Info Only 32 2.88 (1.16) 3.16 (1.11) 0.28 (0.58) Q:  0.46 
D:  0.046 
NM:  0.78 
Q:  0.72 ± 0.10 
D:  -0.19 ± 0.10 
NM:  -0.02 ± 0.10 
Quant 24 3.42 (1.06) 3.54 (1.10) 0.13 (0.74) 
Default 28 3.36 (1.28) 3.36 (1.39) 0.00 (0.61) 
Quant+Default 26 3.27 (1.25) 3.32 (1.31) 0.04 (0.73) 
Above Median 
Basic Info Only 19 3.53 (1.12) 3.68 (1.38) 0.16 (0.83) 
Quant 32 3.22 (1.18) 3.44 (1.22) 0.22 (0.79) 
Default 25 3.36 (1.15) 3.16 (1.21) -0.20 (0.76) 
Quant+Default 26 3.42 (1.14) 3.54 (1.24) 0.12 (0.71) 
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Variable Numeracy Category Group n 
T0 
(mean (SD)) 
T1 
(mean (SD)) 
Change (T1-T0) 
(mean (SD)) 
Final Model    
p-values 
Model Estimate ± Standard 
Error 
FIT Intent 
Below Median 
Basic Info Only 32 2.66 (0.97) 3.00 (1.32) 0.34 (1.26) Q:  0.33 
D:  0.37 
NM:  0.059 
NM*Q:  0.84   
NM*D:  0.80 
Q*ND:  0.30 
NM*Q*D:  
0.025   
Interaction: 
Q for Low NM, No D:  
-0.07 ± 0.31 (p=0.81) 
Q for Low NM, Yes D:  
0.32 ± 0.31 (p=0.31) 
Q for High NM, No D:  
0.71 ± 0.33 (p=0.030) 
Q for High NM, Yes D:   
-0.34 ± 0.32 (p=0.29) 
Quant 24 3.21 (1.14) 3.29 (1.30) 0.08 (1.21) 
Default 28 3.11 (0.99) 3.29 (1.24) 0.18 (0.82) 
Quant+Default 26 2.69 (0.97) 3.32 (1.31) 0.64 (1.38) 
Above Median 
Basic Info Only 19 2.74 (0.73) 3.00 (1.29) 0.26 (0.93) 
Quant 32 2.75 (0.88) 3.72 (1.25) 0.97 (1.28) 
Default 25 2.76 (1.05) 3.64 (1.41) 0.88 (1.05) 
Quant+Default 26 3.00 (0.85) 3.46 (1.17) 0.46 (1.21) 
Decision Conflict 
Below Median 
Basic Info Only 32 29.59 (11.73) 16.06 (7.26) -13.5 (12.46) Q:  0.42 
D:  0.39 
NM:  <0.001 
Q:  -0.86 ± 1.06 
D:  -0.90 ± 1.05 
NM:  -4.06 ± 1.05 
Quant 24 23.50 (10.93) 11.04 (9.88) -12.5 (9.67) 
Default 28 25.11 (9.60) 13.68 (8.50) -11.4 (9.10) 
Quant+Default 26 25.77 (10.93) 12.15 (7.29) -13.6 (10.83) 
Above Median 
Basic Info Only 19 24.26 (8.20) 8.32 (9.02) -15.9 (11.22) 
Quant 32 23.69 (11.94) 9.88 (8.24) -13.8 (10.93) 
Default 25 28.76 (15.61) 9.12 (7.42) -19.6 (15.11) 
Quant+Default 26 25.62 (12.55) 8.69 (7.39) -16.9 (12.98) 
Q=Quantitative, ND=Default, NM=Numeracy 
 
figure 1. Randomized controlled trial with 2 x 2 design  
 
 
 
 
 
 
 
 
 
 
figure 2. Research process diagram 
 
 
 
 
 
 
 
 
 
 figure 3. Study flow diagram of recruitment and follow-up 
 
 
 
 
Appendix:  Sample Slides and Audio Tracks 
 
Basic Information Only Module:  Slides reiterating pros and cons of colonoscopy and stool 
testing presented by an American Cancer Society video presented earlier in the module: 
 
• If no polyps are found, it only needs to be done 
every 10 years
Advantages:
• Most thorough colon test
• Polyps can be removed
• Best at lowering your chance of dying from colon 
cancer
 
The advantages of a colonoscopy are the following:  
It is the most thorough colon test.  Any polyps that 
are found can be removed on the spot.  It is the best 
at lowering your chance of dying from colon cancer.   
And if no polyps are found, it only needs to be done 
every 10 years. 
• Can be expensive
Disadvantages:
• Cleaning out your bowel is uncomfortable
• Has to be done in a hospital or similar facility
• Someone must drive you home
• Very rarely: injury to the colon or rectal bleeding
 
Colonoscopy also has some disadvantages.  The 
preparation – “cleaning out your bowel” – is 
uncomfortable.  The test must be done in a hospital 
or similar facility, and because you will be sedated 
for the procedure, someone has to drive you home. 
Your insurance may not cover the entire cost, so it 
can be expensive.  Finally, having a colonoscopy 
carries some risk. Very rarely people have to be 
hospitalized because of injury to their colon or 
bleeding. 
• Relatively inexpensive
Advantages:
• Easy to perform
• Done at home
• No uncomfortable preparation
 
The advantages of the stool test are that it is easy to 
perform, it is done at home, there is no 
uncomfortable preparation, and it is relatively 
inexpensive. 
Disadvantages:
• Must be done every year
• Can miss polyps or cancers
• If blood is found, you will need to have a 
colonoscopy
 
The disadvantages of the stool test are that it must 
be done every year, it can miss some polyps or 
cancers, and if blood is found, you will need to have 
a colonoscopy. 
 
 
Quantitative Module:  No screening 
 
 
1,000 people with typical risk for colon cancer
 
Consider a group of a thousand people with typical 
risk for colon cancer. This picture shows 1,000 stick 
figures, each one standing for one person. 
With NO test to check for colon cancer:
60 of 1000 get colon cancer
 
People who don’t ever get a colon test have a 6% 
chance of getting colon cancer during their lifetime. 
This means that, out of a thousand people, 60 of 
them will get colon cancer. That’s shown here as a 
yellow shaded box covering 60 people. 
With NO test to check for colon cancer:
60 of 1000 get colon cancer
30 of 1000 die from colon cancer
 
And out of these 60 people who get colon cancer, 30 
of them will die from it; they are shaded red. But it’s 
important to remember that these numbers are just 
for people who don’t ever get a colon test. Getting 
any of the approved tests can lower your chance of 
getting colon cancer and dying from it. 
 
 
 
 
Quantitative Module:  Colonoscopy 
 
 
 
First, let’s look at the effect of getting checked 
regularly with a colonoscopy. 
Colonoscopy risk reduction
With colonoscopy, 4.6 of 1000 die
With NO test, 30 of 1000 die
 
Getting a colonoscopy every 10 years lowers your 
chance of dying from colon cancer, from 3% to 
0.46%. That’s the same as reducing the number of 
people who die from colon cancer from 30 out of a 
thousand (the red line) to just 4.6 out of a thousand 
(the red shaded area). 
Complications of colonoscopy
 
As previously mentioned, colonoscopy does have 
some risk.  Out of 1000 people who have this test, 2 
will have to be hospitalized because of injury to the 
colon or rectal bleeding (shaded blue here). 
 
 
 
Quantitative Module: Stool test and bar chart. 
 
 
Next, consider the stool test. 
Stool Test risk reduction
With the stool test, 6 of 1000 die
With NO test, 30 of 1000 die
 
Getting a stool test every year lowers your 
chance of dying from colon cancer from 3% 
down to 0.6%. That’s the same as reducing the 
number of people who die from colon cancer 
from 30 out of 1000 (the red line) to just 6 out 
of 1000 (the red shaded area). 
Stool Tests leading to colonoscopy
50 of 1000 who get a 
stool test will need a 
follow-up colonoscopy
 
As you’ve already heard, if the test shows blood 
in your stool, you’ll need a colonoscopy. Out of 
1000 people who get the stool test, about 50 
will have blood in their stool and will therefore 
need a colonoscopy. 
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As you can see, both colonoscopy and stool 
testing lower your chance of dying from colon 
cancer.  Out of 1000 people who never get a 
colon test, 30 will die from colon cancer, as 
shown here. If they get checked with the stool 
test every year, just 6 will die.  And if they have a 
colonoscopy every 10 years, only 4.6 will die. 
 
Nudge Module: 
 
 
Given the advantages and disadvantages of both 
tests, many people have a hard time deciding which 
test to choose. 
• Protects you almost as much
• Either test is better than no 
screening
• Can always get a 
colonoscopy later
 
Many people who do not want a colonoscopy or are 
unsure about which test to choose get a stool test, 
and it’s a perfectly reasonable option. The stool test 
protects you almost as much as colonoscopy. Either 
test protects you much more than getting no 
screening at all. And even if you choose to get the 
stool test now, you can always get a colonoscopy 
later. 
If you don’t want to have a colonoscopy 
right now, or are unsure about which test to 
choose, the stool test could be the right one 
for you.
 
In summary, if you don’t want to have a colonoscopy 
right now, or don’t know which test to choose, the stool 
test could be the right one for you. 
 
All modules:  Conclusion slide 
 
 
Your doctor may recommend a particular test, but 
the decision is yours to make. In the end, what really 
matters is that you make a decision that’s right for 
you. 
 
Figure S1. Change in Perceived CRC Risk and Decision Conflict from T0 to T1 (Mean ± SE) 
 
 
Perceived CRC risk at T0 and T1 for:  a: all participants;  b: patients with low numeracy;  c: patients with high numeracy. 
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Decision conflict at T0 and T1 for:  d: all participants;  e: patients with low numeracy;  f: patients with high numeracy. 
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Figure S2. Change in CRC Screening Intent, Colonoscopy, and FIT from T0 to T1 (Mean ± SE) 
 
CRC screening intent at T0 and T1 for:  a: all participants;  b: patients with low numeracy;  c: patients with high numeracy. 
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Colonoscopy intent at T0 and T1 for:  d: all participants;  e: patients with low numeracy;  f: patients with high numeracy. 
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FIT intent at T0 and T1 for:  g: all participants;  h: patients with low numeracy;  i: patients with high numeracy. 
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